Cargando…
Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting
BACKGROUND: Dabigatran etexilate may be underutilized in geriatric patients because of inadequate clinical experience in individuals with severe renal impairment and post-marketing reports of bleeding events. Assessing the degree of anticoagulation may improve the risk:benefit ratio for dabigatran....
Autores principales: | Brunetti, Luigi, Sanchez-Catanese, Betty, Kagan, Leonid, Wen, Xia, Liu, Min, Buckley, Brian, Luyendyk, James P., Aleksunes, Lauren M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858862/ https://www.ncbi.nlm.nih.gov/pubmed/27158246 http://dx.doi.org/10.1186/s12959-016-0084-2 |
Ejemplares similares
-
Cost of dabigatran for atrial fibrillation
por: Gage, Brian F
Publicado: (2011) -
Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers
por: Ćelap, Ivana, et al.
Publicado: (2020) -
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
por: Weltermann, A., et al.
Publicado: (2012) -
Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
por: Stöllberger, Claudia, et al.
Publicado: (2012) -
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
por: Huber, K, et al.
Publicado: (2013)